CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 2025 Announcements . Clinical . News 07.05.2025
Preliminary results from SCENESSE® adolescent EPP study 2025 Announcements . Clinical . News 10.02.2025
SCENESSE® Argentinian distribution agreement 2025 Announcements . Clinical . News . Regulatory 17.01.2025
SCENESSE® dosage expansion under review by European Medicines Agency 2024 Announcements . Clinical . News . Regulatory 20.11.2024
CLINUVEL prioritises three strategic programs 2024 Announcements . Clinical . News . Regulatory 18.11.2024
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP 2024 Announcements . Clinical . News . Regulatory 01.10.2024
SCENESSE® data to be presented at global porphyria conference 2024 Announcements . Clinical . News . Regulatory 20.09.2024
Afamelanotide assists DNA repair response following UV radiation 2024 Announcements . Clinical . News 05.07.2024
SCENESSE® European Orphan Drug Designation for Variegate Porphyria 2024 Announcements . Clinical . News 24.06.2024
Technical note: Afamelanotide as MC1R-targeted therapy in Parkinson’s [PD] 2024 Announcements . Clinical . News 18.06.2024